Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060138 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00060138 is a Phase 1 study that has completed, run by Chugai Pharmaceutical.
The verdict
NCT00060138, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than zoledronate in treating women who have breast cancer and bone metastases. PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with that of zoledronate in treating women who have breast cancer and bone metastases.
Interventions
- DRUG zoledronic acid
- BIOLOGICAL monoclonal antibody CAL
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060138
The ClinicalTrials.gov registry entry for NCT00060138 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which zoledronic acid is the first listed.
NCT00060138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060138 about?
NCT00060138 is a clinical study titled "Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than ...
What is the current status of trial NCT00060138?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-11.
What interventions are being tested in trial NCT00060138?
The interventions under investigation include: zoledronic acid (DRUG), monoclonal antibody CAL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00060138?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.